NASDAQ:CGENCompugen Stock Price, Forecast & News

Compugen's stock was trading at $11.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CGEN stock has increased by 30.2% and is now trading at $15.40. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Compugen.

Compugen is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Compugen.

Compugen Ltd. (NASDAQ:CGEN) issued its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). During the same quarter in the prior year, the business posted ($0.14) earnings per share. View Compugen's earnings history.

7 analysts have issued 12-month target prices for Compugen's stock. Their forecasts range from $13.00 to $28.00. On average, they anticipate Compugen's stock price to reach $18.57 in the next year. This suggests a possible upside of 20.6% from the stock's current price. View analysts' price targets for Compugen.

News articles about CGEN stock have been trending somewhat positive on Saturday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Compugen earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View the latest news about Compugen.

Some companies that are related to Compugen include China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), bluebird bio (BLUE), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Bill.com (RVMD), Twist Bioscience (TWST), Alector (ALEC), SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Editas Medicine (EDIT) and I-Mab (BDTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Gilead Sciences (GILD), Novavax (NVAX), Pluristem Therapeutics (PSTI), Inovio Pharmaceuticals (INO), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Alibaba Group (BABA).

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CGEN stock can currently be purchased for approximately $15.40.

Compugen has a market capitalization of $1.05 billion and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe.

The official website for Compugen is www.cgen.com.

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]